Triple-negative breast cancer (TNBC) comprises a heterogeneous disease group defined by lack of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression and is often associated with increased genomic instability, high mitotic rates and poor prognosis (1, 2). The gene discussed is ESR1; the disease is triple-negative breast carcinoma.